PPARδ and its ligand erucic acid may act anti-tumoral, neuroprotective, and myelin protective in neuroblastoma, glioblastoma, and Parkinson's disease

Altinöz, Meriç A.; Elmacı, İlhan; Hacımüftüoğlu, Ahmet; Ozpinar, Alp; Hacker, Emily; Özpınar, Aysel

doi:10.1016/j.mam.2020.100871

Cited by 30 publications

(17 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Parkinson’s disease is a chronic disease with no clinical cure ( Guo et al, 2019 ; Altinoz et al, 2020 ). However, Parkinson’s disease can be alleviated and treated with optogenetics.…”

Section: Nervous System-based Clinical Researchmentioning

confidence: 99%

The Roles of Optogenetics and Technology in Neurobiology: A Review

Chen

Liang

et al. 2022

Front. Aging Neurosci.

View full text Add to dashboard Cite

Optogenetic is a technique that combines optics and genetics to control specific neurons. This technique usually uses adenoviruses that encode photosensitive protein. The adenovirus may concentrate in a specific neural region. By shining light on the target nerve region, the photosensitive protein encoded by the adenovirus is controlled. Photosensitive proteins controlled by light can selectively allow ions inside and outside the cell membrane to pass through, resulting in inhibition or activation effects. Due to the high precision and minimally invasive, optogenetics has achieved good results in many fields, especially in the field of neuron functions and neural circuits. Significant advances have also been made in the study of many clinical diseases. This review focuses on the research of optogenetics in the field of neurobiology. These include how to use optogenetics to control nerve cells, study neural circuits, and treat diseases by changing the state of neurons. We hoped that this review will give a comprehensive understanding of the progress of optogenetics in the field of neurobiology.

show abstract

“…Parkinson’s disease is a chronic disease with no clinical cure ( Guo et al, 2019 ; Altinoz et al, 2020 ). However, Parkinson’s disease can be alleviated and treated with optogenetics.…”

Section: Nervous System-based Clinical Researchmentioning

confidence: 99%

The Roles of Optogenetics and Technology in Neurobiology: A Review

Chen

Liang

et al. 2022

Front. Aging Neurosci.

View full text Add to dashboard Cite

show abstract

“…It has been demonstrated that in the rotenone-prompted rat model of PD, a PPAR-β/δ agonist, namely GW-501516, safeguards DArgic nerve cells from destruction provoked by deleterious substances, as well as upgrades behavioral performance by diminishing ER-related stress in PD. Moreover, in the MPTP instigated PD model of mice, a decline in nucleotide-binding domain and leucine-rich-repeat-protein 3 (NLRP3) inflammasome-related nerve cell inflammation is rendered by PPAR-β/δ agonists [ 174 ].…”

Section: Experimental Studies Portraying the Deep Insights Into The Neuroprotective Role Of Ppar Agonists In Pdmentioning

confidence: 99%

Elucidating the Neuroprotective Role of PPARs in Parkinson’s Disease: A Neoteric and Prospective Target

Behl

Madaan

Sehgal

et al. 2021

IJMS

View full text Add to dashboard Cite

One of the utmost frequently emerging neurodegenerative diseases, Parkinson’s disease (PD) must be comprehended through the forfeit of dopamine (DA)-generating nerve cells in the substantia nigra pars compacta (SN-PC). The etiology and pathogenesis underlying the emergence of PD is still obscure. However, expanding corroboration encourages the involvement of genetic and environmental factors in the etiology of PD. The destruction of numerous cellular components, namely oxidative stress, ubiquitin-proteasome system (UPS) dysfunction, autophagy-lysosome system dysfunction, neuroinflammation and programmed cell death, and mitochondrial dysfunction partake in the pathogenesis of PD. Present-day pharmacotherapy can alleviate the manifestations, but no therapy has been demonstrated to cease disease progression. Peroxisome proliferator-activated receptors (PPARs) are ligand-directed transcription factors pertaining to the class of nuclear hormone receptors (NHR), and are implicated in the modulation of mitochondrial operation, inflammation, wound healing, redox equilibrium, and metabolism of blood sugar and lipids. Numerous PPAR agonists have been recognized to safeguard nerve cells from oxidative destruction, inflammation, and programmed cell death in PD and other neurodegenerative diseases. Additionally, various investigations suggest that regular administration of PPAR-activating non-steroidal anti-inflammatory drugs (NSAIDs) (ibuprofen, indomethacin), and leukotriene receptor antagonists (montelukast) were related to the de-escalated evolution of neurodegenerative diseases. The present review elucidates the emerging evidence enlightening the neuroprotective outcomes of PPAR agonists in in vivo and in vitro models experiencing PD. Existing articles up to the present were procured through PubMed, MEDLINE, etc., utilizing specific keywords spotlighted in this review. Furthermore, the authors aim to provide insight into the neuroprotective actions of PPAR agonists by outlining the pharmacological mechanism. As a conclusion, PPAR agonists exhibit neuroprotection through modulating the expression of a group of genes implicated in cellular survival pathways, and may be a propitious target in the therapy of incapacitating neurodegenerative diseases like PD.

show abstract

“…The heterogeneity analysis was employed to test whether the total variance mainly resulted from between-study variance or from both within-and between-study variance. The analysis results showed that the total variance among different studies was 7.9, which was smaller than the expected variance (17) given that all studies have the same actual effect. Our results indicated that the between-study variance was not the primary source contributing to total variance among these studies (p value = 0.96).…”

Section: Multiple Linear Regression Analysis Results Mlr Resultsmentioning

confidence: 73%

“…Most noticeably, PPARG was shown to inhibit multiple cytokine signaling pathways, which have been demonstrated to play an important role in the pathophysiology of MDD [15]. On the one hand, PPARD activation blocks the synthesis of inflammatory cytokines, including IL1β, IL6, and TNFα [16], which explains the fact that PPARD agonists downregulate the expression of these cytokines [17]. On the other hand, serum TNFα, IL6, and IL1β were implicated as important factors in the psychopathology of acute-phase MDD [18], which were found to stimulate behavioral changes of MDD [19].…”

Section: Discussionmentioning

confidence: 99%

PPARD May Play a Protective Role for Major Depressive Disorder

Yang

et al. 2021

PPAR Research

View full text Add to dashboard Cite

Activation of PPARD has been shown to inhibit depressive behaviors and enhances neurogenesis. However, whether PPARD is involved in the pathological development of major depressive disorder (MDD) is largely unknown. To explore the potential connection between PPARD and MDD, we first conducted a literature-based data mining to construct a PPARD-driven MDD regulating network. Then, we tested the PPARD expression changes in MDD patients from 18 independent MDD RNA expression datasets, followed by coexpression analysis, multiple linear regression analysis, and a heterogeneity analysis to study the influential factors for PPARD expression levels. Our results showed that overexpression of PPARD could inhibit inflammatory cytokine signaling pathways and the ROS and glutamate pathways that have been shown to play important roles in the pathological development of MDD. However, PPARD could also activate nitric oxide formation and ceramide synthesis, which was implicated as promoters in the pathogenesis of MDD, indicating the complexity of the relationship between PPARD and MDD. PPARG presented significant within- and between-study variations in the 18 MDD datasets ( p value = 0.97), which were significantly associated with the population region (country) and sample source ( p < 2.67 e − 5 ). Our results suggested that PPARD could be a potential regulator rather than a biomarker in the pathological development of MDD. This study may add new insights into the understanding of the PPARD-MDD relationship.

show abstract

PPARδ and its ligand erucic acid may act anti-tumoral, neuroprotective, and myelin protective in neuroblastoma, glioblastoma, and Parkinson's disease

Cited by 30 publications

References 69 publications

The Roles of Optogenetics and Technology in Neurobiology: A Review

The Roles of Optogenetics and Technology in Neurobiology: A Review

Elucidating the Neuroprotective Role of PPARs in Parkinson’s Disease: A Neoteric and Prospective Target

PPARD May Play a Protective Role for Major Depressive Disorder

Contact Info

Product

Resources

About